关于决策援助的发展及其在患有注意力缺陷/多动障碍的成年人中接受度,关于在缓解后停止治疗的决定
Noa Tsujii1,2, Takashi Okada3, Masahide Usami4
1Department of Child Mental Health and Development Toyama University Hospital Toyama Toyama Japan.
PCN reports : psychiatry and clinical neurosciences
|June 13, 2024
概括
这项研究开发了一种帮助成年ADHD和他们的医生决定是否继续或停止缓解后的ADHD药物治疗的帮助. 患者和提供者都认为这种援助是可以接受的.
科学领域:
- 神经发育障碍 神经发育障碍
- 临床决策 临床决策
- 患者参与 患者参与
背景情况:
- 共享决策 (SDM) 是当前ADHD临床指南的核心.
- 在成年ADHD管理的SDM中存在挑战,特别是关于缓解后的药物治疗.
- 要支持这些复杂的药物决策,需要一个决策辅助器 (DA).
研究的目的:
- 为患有多动症的成年患者开发一种决策辅助 (DA).
- 帮助决定是否在缓解后继续或停止服用ADHD药物.
- 确保DA符合患者决策辅助器的既定质量标准.
主要方法:
- 根据国际患者决策辅助标准 (IPDAS) 系统地开发了DA.
- 基于药物后果的系统审查和元分析,创建原型.
- 混合方法问卷 (阿尔法可接受性测试) 与成年ADHD患者和医疗保健提供者进行细化.
- 根据IPDAS标准对最终DA的评估.
主要成果:
- 开发的DA包括ADHD信息,药物选择,利弊和价值澄清练习.
- 患者 (n=20) 发现DA是可以接受的 (85%的语言,75%的信息,53%的平衡呈现).
- 医疗保健提供者 (n=19) 提供了积极的反.
- 最终的DA成功满足了所有六个IPDAS要求的标准.
结论:
- 开发的DA可以促进ADHD药物持续/停止缓解后的SDM.
- 需要进一步的研究来验证DA在多样化的ADHD患者群体中的影响.
- 该DA旨在改善患者-提供者沟通,并在ADHD治疗管理中做出明智的选择.
更多相关视频
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
15.7K
12:55Multimodal Protocol for Assessing Metacognition and Self-Regulation in Adults with Learning Difficulties
Published on: September 27, 2020
8.4K
相关概念视频
Attention-Deficit/Hyperactivity Disorder
55
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
55
Drug Therapy
42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
42
Modeling in Therapy
65
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
65
Oppositional Defiant Disorder
24
A persistent pattern of angry or irritable mood, defiant behavior, or vindictiveness characterizes Oppositional Defiant Disorder (ODD). Symptoms must occur over at least six months, involve interactions with individuals beyond siblings, and meet specific diagnostic criteria to be clinically significant. The disorder affects emotional regulation, social interactions, and behavior, often manifesting early in life and influencing long-term development and functioning.
Diagnostic Criteria and...
Diagnostic Criteria and...
24
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Behavior Modification
139
Behavioral approaches have often been criticized for ignoring mental processes and focusing solely on observable behavior. However, these approaches provide an optimistic perspective for individuals seeking to change their behaviors. Rather than concentrating on intrinsic personality traits, behavioral approaches suggest that even longstanding habits can be modified by changing the reward contingencies that maintain them.
A real-world application of operant conditioning principles is applied...
A real-world application of operant conditioning principles is applied...
139
